Combination therapy of allergic rhinitis: efficacy, safety and impact on quality of life

Currently, allergic rhinitis is one of the most common allergic diseases, the importance of which is often underestimated by both, doctors and patients themselves, and leads to the severity raising, the physical, professional and social activity decreasing, the sleep disturbance and the quality of life impaired. Despite the modern medicines availability the control level over the symptoms allergic rhinitis remains low in routine clinical practice. Not seeing a quick result of the intranasal glucocorticosteroids use, which have been anti-inflammatory and pathogenetic effects, patients refuse them in favor the fast-acting decongestants, and it can be underline to a chronization and the adverse events. The use of combined intranasal glucocorticosteroids and antihistamines, which have additives effect on the main pathogenesis stages of the allergic inflammation, allows to quickly achieve the control over the most pronounced rhinitis symptoms and can increase the adherence to therapy. This review presents the results of clinical studies and key characteristics of the new nasal spray of the olopatadine and mometasone fixed combination, confirming the high efficacy and good safety profile of olopatadine + mometasone. The olopatadine and mometasone fixed combination using provides a rapid nasal and ocular symptoms resolved in patients with allergic rhinitis, ultimately leading to the quality of life improvement.